Recent clinical trial announcements sparked excitement and seemed to move exponentially upwards!
However, enhancing the effectiveness of medications that targeted the adenosine route, overcoming obstacles related to resistance and immunosuppression, and boosting treatment for patients in need remained a huge challenge for the field.
This is why the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit was devoted to reuniting 60+ industry and academic thought leaders to analyze the most recent advances of the last year.
Across 3 days of jam-packed content, this meeting aimed to improve understanding of adenosine signaling in the TME (tumor microenvironment), rationalize drug combinations to improve patient responses, and explore tools that quantified adenosine to select the patient.
What's More? Check Out These Unmissable Highlights:
Prepare for all outcomes of the pivotal phase 3 trial everyone is waiting for. Gain unique updates from leading pharma into how mAB candidates are advancing and what their plans are for future development with AstraZeneca
Explore the core oncological concepts that underpin adenosine’s role in carcinogenesis. Learn how Adenosine induces hypoxia and angiogenesis mechanisms in cancer, and how targeting these improve patient outcomes with Harvard Medical School
Use novel trial design concepts to gain an enhanced understanding of the interactions between Adenosine, PD/PDL-1 and other immunotherapies. Select the right combination partner or bispecific components with Phanes Therapeutics and Elpiscience
Enhance your understanding of little-known components of the adenosine system. Gain a comprehensive understanding of the underpinning immunosuppressive mechanisms caused by adenosine signaling and enzymology with Rutgers University and the University of Turku
Forecast the future of the adenosine field. Assess the potential outcomes of approval or major failure with ITeos Therapeutics and Trishula Therapeutics
Our exclusive attendees left this definitive conference equipped with novel ideas, actionable lessons learned and new connections enabling them to progress their adenosine-pathway targeted cancer immunotherapies to the clinic.
